Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/SANGAMO THERAPEUTICS INC/ NT 10-Q

SEC Filing · NT 10-Q

SANGAMO THERAPEUTICS INC

SGMOQOTCEQUITYCurrent

SEC Filing

Filed Aug 17, 2026Accepted Aug 17, 2026, 5:10 PM EDTCIK 1001233Accession 0001193125-26-354282
View company →Permanent SEC source ↗
Share

Company context

Sangamo Therapeutics is a genomic medicine company that pioneered the development of zinc finger and capsid delivery technologies to address serious neurological and rare diseases. The Company is currently operating under court supervision in Chapter 11. To learn more, visit www.sangamo.com.

Current securities

SGMOQOTC · EQUITY · Current

Recent company filings

  1. Bankruptcy or Receivership · Completion of Acquisition or Disposition of AssetsSep 21, 2026
  2. Bankruptcy or Receivership · Completion of Acquisition or Disposition of Assets · Regulation FD DisclosureSep 8, 2026
  3. Entry into a Material Definitive Agreement · Bankruptcy or ReceivershipAug 28, 2026
  4. SCHEDULE 13G/A filingAug 14, 2026
  5. Other EventsAug 13, 2026

As-filed source

Primary evidence
As filedOpen full document ↗